Shujie Lu
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Head-to-Head Comparison of an IGF-1R Inhibitor Versus Intravenous Glucocorticoid for Active Thyroid Eye Disease: Design of a Randomized Clinical Trial.
Journal: Ophthalmology and therapy
Published: April 01, 2026
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: October 09, 2025
Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.
Journal: Ophthalmology science
Published: February 08, 2025
Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema.
Journal: BMJ open ophthalmology
Published: November 01, 2024
Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized, Double-Masked, Active-Controlled, Noninferiority, Phase II Trial.
Journal: Ophthalmology. Retina
Published: December 22, 2023
A Novel Bispecific Fusion Protein Targeting C3b/C4b and VEGF in Patients With nAMD: A Randomized, Open-Label, Phase 1b Study.
Journal: American journal of ophthalmology
Published: August 08, 2022
Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
Journal: Science translational medicine
Published: June 01, 2022
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.
Journal: The Lancet. Rheumatology
Published: June 22, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026